Tuesday, October 28, 2008

J&J move into preventive health in US

By Tracy Staton

Remember Johnson & Johnson's Office of Strategy and Growth set up during that big reorg last year? Well, it's delivering on its mission. J&J is buying into preventive healthcare with the acquisition of HealthMedia, an online health-coaching firm that also offers software to help employers reduce healthcare costs. HealthMedia will form the core of a new division, headed up by Nicholas Valeriani, the chief of that strategy/growth office.

"We could now create a suite of products and services that are further upstream," Valeriani told the Wall Street Journal, adding that doing so might help stem the rising tide of healthcare costs.

The move marks another sort of diversification for J&J, which already has 250 operating companies in three healthcare segments: pharmaceuticals, medical devices and diagnostics, and consumer health.

- see J&J's release
- read the Wall Street Journal
story
----------------------------------
GSK Bio, Singapore
----------------------------------

Friday, October 24, 2008

Crude oil price (USD/bbl)

October 2008 Vol. 229 No. 10


with the recession, its' coming down... 
don't know whether the prices gonna tumble too,
me thinks very unlikely

Wednesday, October 22, 2008

NZ biotech to inject pig cells into diabetics

NZ biotech to inject pig cells into diabetics
October 21, 2008 — 9:01am ET | By John Carroll

After 10 years of work, Living Cell Technologies in New Zealand has received the green light from the government to launch an unusual human trial of a new diabetes therapy. Volunteers in the trial will be injected with pig cells, an approach the company believes will help to regulate the way their bodies produce insulin. The cells are first coated with purified sea weed so that their immune system won't recognize them and attack the cells.

"Once they have one of these implants, which is a very simple procedure, it seems to take away the wild swings (in insulin production) and helps the management," says company founder David Collinson. The two-year trial gets underway in February with eight patients. Collinson says that NZ regulators had dragged their feet for years before approving the trial.

Living Cell Technologies says it already has one such trial underway in Russia and has been gathering positive data from volunteers in that study.

- check out LCT's release
- read the
report from the AAP

Related Articles:
Piglet cells used to treat Type 1 diabetes
LCT gets $6M in share capital
LCT's stem cell research should be encouraged (Sept. 2006)

http://www.news.com.au/story/0,10117,24529871-401,00.html?from=public_rss


~ peace ~
محمدغزالي
Md Ghazali
----------------------------------
GSK Bio, Singapore
DID: 65-6496 3072
----------------------------------

Monday, October 20, 2008

Hadith of the Week

Hadith 12: Being concerned with beneficial matters

On the authority of Abu Hurairah, radiyallahu 'anhu, who said : The Messenger of Allah, saw, said :

"Part of the perfection of someone's Islam is his leaving alone that which does not concern him."

[Hadith hasan - Recorded by Tirmidhi]



For further reading: http://fortyhadith.iiu.edu.my/hadith12.htm

~ peace ~
  محمدغزالي
Md Ghazali

Wednesday, October 15, 2008

Wednesday, October 08, 2008

5 Dimension of Leadership


Link: http://www.mckinseyquarterly.com/PDFDownload.aspx?L2=18&L3=31&ar=2193&srid=17

No more cold meds for kids under four

No more cold meds for kids under four

By Christe Bruderlin-Nelson

Big pharma will be taking a voluntary hit in its $300 million over-the-counter market for children's cold medicines. While readily available at drugstores everywhere, physicians and other experts have repeatedly called their safety and efficacy into question, although the Consumer Healthcare Products Association (CHPA)--a cold-medicine industry group--maintains the drugs are safe when used appropriately. CHPA represents major drugmakers including Johnson & Johnson, Procter & Gamble and Novartis.

Leading manufacturers of the medications will change the labels to say, "do not use" in children under the age of four, as well as add language to medications containing antihistamine products essentially telling parents not to drug their children for the purposes of helping them sleep. Major companies like McNeil Consumer Healthcare (a division of Johnson & Johnson that makes Children's Sudafed, Children's Benadryl and PediaCare cough and cold medicines) and Wyeth (which makes Dimetapp and Robitussin cough and cold medicines) were among the pharma giants spearheading the voluntary effort.

While some groups, including physicians' groups, requested a ban on the medications for all children under the age of six, the FDA rejected the plea on Monday. On Tuesday, however, drug companies took an ethical leap anyway and publicly advised parents not to use OTC cough and cold remedies in children under the age of four. A previous advisory recommended against giving the medications to children under two and drug companies pulled all infant cough and cold meds off the market a year ago. Some say the hesitancy of the FDA to initiate a broader ban might rest on fears that, without the children's option, desperate parents might try to give children adult medications to relieve symptoms.

Prominent physician groups, including the American Academy of Pediatricians, say the research is weak on the drugs and that, considering the risks and the dearth of safety and efficacy information, there isn't a solid reason to use the medications in children under the age of six. In fact, an earlier CDC study found that each year approximately 7,000 children ages 11 and younger (with most between two and five years) end up in the emergency room after ingesting cough and cold medicines designed for children. Likewise, there were reports of 10 infant deaths associated with OTC cold medicines in 2006, according to Arizona researchers.

A spokesperson for Johnson & Johnson in Canada said that the company will not put the warnings on Canadian products, however.

- here's the LA Times blog post
- find out what the Washington Post
said

Sunday, October 05, 2008

OSIM Corporate Triathlon



OSIM Corporate Triathon

I'm running the last leg - 5km run - I am now in training